Atıf İçin Kopyala
Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., Dal M. S., ...Daha Fazla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.22, sa.3, ss.169-173, 2022 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
22
Sayı:
3
-
Basım Tarihi:
2022
-
Doi Numarası:
10.1016/j.clml.2021.09.010
-
Dergi Adı:
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
-
Sayfa Sayıları:
ss.169-173
-
Anahtar Kelimeler:
Chronic lymphocytic leukemia, Bruton tyrosine kinase, Ibrutinib, Relapsed/refractory, p53 mutation, CHRONIC LYMPHOCYTIC-LEUKEMIA
-
Erciyes Üniversitesi Adresli:
Evet
Özet
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice.